We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01238692
Recruitment Status : Active, not recruiting
First Posted : November 11, 2010
Last Update Posted : December 6, 2016
Sponsor:
Collaborators:
Quebec Clinical Research Organization in Cancer
Novartis
Hoffmann-La Roche
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital